Share information
203.90 €
+0.20 %
12/10/2026 17:35
+0.20 %
Open
High
Low
Volume
204.50 €
206.30 €
203.60 €
140,585
Latest News
30-Sep-2026
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating hidradenitis suppurativa
29-Sep-2026
UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
09-Sep-2026
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA[®] (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
08-Sep-2026
UCB opens ‘Expressing Epilepsy’ art exhibition featuring acclaimed artists living with epilepsy